Peripheral Arterial Disease Management

Introduction to PAD Treatment

The European Society of Cardiology recommends supervised exercise training (SET) combined with comprehensive optimal medical therapy (OMT) as the first-line treatment for Peripheral Arterial Disease (PAD), with revascularization considered only after a 3-month trial of this approach in patients with persistent lifestyle-limiting symptoms 1, 2, 3

The American College of Cardiology recommends SET as the cornerstone of PAD treatment, carrying a Class I, Level A recommendation, with a frequency of at least 3 times per week, duration of at least 30 minutes per session, and program length of at least 12 weeks 1, 2
The European Heart Society recommends walking to moderate-severe claudication pain (77-95% maximal heart rate or 14-17 on Borg scale) for optimal benefit, with sessions supervised by clinical exercise physiologists or physiotherapists 1, 2, 3

The American Heart Association recommends statin therapy for all PAD patients, regardless of baseline cholesterol levels, with a target LDL-C <55 mg/dL (<1.4 mmol/L) and ≥50% reduction from baseline, as well as antiplatelet therapy to reduce major adverse cardiovascular events (MACE) 1, 4, 5
The European Society of Cardiology recommends blood pressure management with antihypertensive therapy, targeting systolic BP 120-129 mmHg, and avoiding dual RAS blockade (ACE inhibitor + ARB) 4, 6

The American College of Cardiology recommends cilostazol as adjunctive therapy to improve walking distance if exercise therapy alone is insufficient, though side effects lead to 20% discontinuation within 3 months 4, 8

The European Society of Cardiology recommends revascularization only after a 3-month trial of OMT and exercise therapy in patients with persistent lifestyle-limiting symptoms and impaired quality of life, and not for asymptomatic PAD or prevention of progression to chronic limb-threatening ischemia 1, 7, 5, 8

The European Heart Society recommends regular follow-up at least annually to assess clinical and functional status, medication adherence, limb symptoms, and cardiovascular risk factors, with duplex ultrasound as needed 7, 5, 8